pillbase.ru

Oxbryta

Active substance: voxelotor

voxelotor

Centralised EU authorisationSuspended

Marketing holder: Pfizer Europe MA EEIG

Verified 2026-10-09 · EMA

Analogues in other countries
Composition
Analogues by country

Products with the same active substance registered in other countries.

CountryProducts
US 3
  • OXBRYTA
    TABLET, FILM COATED · VOXELOTOR 300 mg/1
    72786-102
    Global Blood Therapeutics, Inc, A subsidiary of Pfizer Inc.
  • OXBRYTA
    TABLET, FOR SUSPENSION · VOXELOTOR 300 mg/1
    72786-111
    Global Blood Therapeutics, Inc, A subsidiary of Pfizer Inc.
  • OXBRYTA
    TABLET, FILM COATED · VOXELOTOR 500 mg/1
    72786-101
    Global Blood Therapeutics, Inc, A subsidiary of Pfizer Inc.
Import and control

Control by country

  • United Statesprescription only

    Source: openFDA NDC · record 01a1208c-2cfa-7291-9007-f40fa474e055,01a12097-46e4-780e-ab23-f7e278899780,01a1209e-6a38-7230-bbe2-ab9f98263b96;count=3 · valid from 2026-10-09 · verified 2026-10-09

More on control status
Registration
Registration number
EMEA/H/C/004869
Registration status
Suspended
ATC code
B06AX03
Sources
  • product · EMA · EMEA/H/C/004869 · Verified 2026-10-09
  • registration_status · EMA · EMEA/H/C/004869 · Verified 2026-10-09
  • ingredients.0 · EMA · EMEA/H/C/004869 · Verified 2026-10-09